X4 Pharmaceuticals (XFOR) announced positive new clinical data from its now completed Phase 2 clinical trial evaluating mavorixafor, an oral ...

Completing the study also satisfied an FDA requirement for the upcoming Phase 3 trials of AD04. Also Read ... Cohort 2 (n=24) ...

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...

Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch of Iqirvo® (elafibranor)1 on track with ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Greetings, and welcome to the Acurx Pharmaceuticals, Inc. Third ...

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study of uliledlimab ...

In Japan, clinical use is climbing faster, with about 4,500 people now on the drug. ARIA rates in Japan are half those in the U.S., which was also the case in the Phase 3 Clarity trial. Meanwhile, use ...

In a trial with 11 patients with midline diffuse glioma, 9 showed benefits from the cellular therapy. In one case, the tumor ...

An international, Phase III clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare ...

Regeneron’s clinical trials are at the core of this mission. Regeneron is grateful to all clinical trial participants — ...

A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery ...